For research use only. Not for therapeutic Use.
Gilteritinib-d8 (CAS: 2377109-74-3), a high-quality pharmaceutical research compound designed for advanced oncology and hematological studies. As a deuterated analog of Gilteritinib, it offers enhanced stability and improved pharmacokinetic properties. Gilteritinib-d8 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for leukemia and other cancers. Trusted by leading laboratories, Gilteritinib-d8 is your go-to solution for cutting-edge cancer research. Unlock new possibilities in leukemia treatment with Gilteritinib-d8, where innovation meets reliability.
| Catalog Number | S000125 |
| CAS Number | 2377109-74-3 |
| Molecular Formula | C29H36D8N8O3 |
| Purity | ≥95% |
| Target | FLT3 |
| IUPAC Name | 6-ethyl-3-[3-methoxy-4-[4-(2,2,3,3,5,5,6,6-octadeuterio-4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide |
| InChI | InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)/i13D2,14D2,15D2,16D2 |
| InChIKey | GYQYAJJFPNQOOW-DBVREXLBSA-N |
| SMILES | [2H]C1(C(N(C(C(N1C)([2H])[2H])([2H])[2H])C2CCN(CC2)C3=C(C=C(C=C3)NC4=NC(=C(N=C4C(=O)N)CC)NC5CCOCC5)OC)([2H])[2H])[2H] |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML). 2014 ASCO Annual Meeting. [3]. Mori M, et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017 Oct;35(5):556-565. |
